クリオピリン関連周期症候群(CAPS)の世界市場:パイプラインインサイト2021

【英語タイトル】Cryopyrin-Associated Periodic Syndrome (CAPS) - Pipeline Insight, 2021

DelveInsightが出版した調査資料(DELV21SE073)・商品コード:DELV21SE073
・発行会社(調査会社):DelveInsight
・発行日:2021年7月
・ページ数:60
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:世界
・産業分野:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥222,000見積依頼/購入/質問フォーム
Global Site LicenseUSD4,500 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

DelveInsight’s, “Cryopyrin-Associated Periodic Syndrome (CAPS) – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage

Cryopyrin-Associated Periodic Syndrome (CAPS) Understanding
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
Cryopyrin-associated periodic syndrome or syndromes (CAPS), also known as cryopyrinopathies, are genetic autoinflammatory syndromes defined by ‘gain-of-function’ mutations affecting the cryopyrin protein. Cryopyrin-associated periodic syndromes are all autosomal dominant genetic conditions, meaning only one copy of the abnormal gene is required to develop the clinical syndrome. CAPS comprises 3 disorders on a continuum of severity: severe CINCA syndrome, intermediate Muckle-Wells syndrome (MWS) and milder familial cold urticaria (FCAS).

Cryopyrin-Associated Periodic Syndrome (CAPS) – Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline landscape is provided which includes the disease overview and Cryopyrin-Associated Periodic Syndrome (CAPS) treatment guidelines. The assessment part of the report embraces, in depth Cryopyrin-Associated Periodic Syndrome (CAPS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cryopyrin-Associated Periodic Syndrome (CAPS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Cryopyrin-Associated Periodic Syndrome (CAPS) R&D. The therapies under development are focused on novel approaches to treat/improve Cryopyrin-Associated Periodic Syndrome (CAPS).

Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs Chapters
This segment of the Cryopyrin-Associated Periodic Syndrome (CAPS) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cryopyrin-Associated Periodic Syndrome (CAPS) Emerging Drugs
• DFV 890: Novartis
DFV 890 is a NLRP3 protein inhibitor being developed by Novartis. Currently, it is in Phase II stage of development to treat Cryopyrin-associated periodic syndromes.

• IZD334: Inflazome
IZD334 is a NLRP3 protein inhibitors. Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases. Acquisition of Inflazome had given Roche full rights to the Inflazome portfolio.
Further product details are provided in the report……..

Cryopyrin-Associated Periodic Syndrome (CAPS): Therapeutic Assessment
This segment of the report provides insights about the different Cryopyrin-Associated Periodic Syndrome (CAPS) drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Cryopyrin-Associated Periodic Syndrome (CAPS)
There are approx. 3+ key companies which are developing the therapies for Cryopyrin-Associated Periodic Syndrome (CAPS). The companies which have their Cryopyrin-Associated Periodic Syndrome (CAPS) drug candidates in the most advanced stage, i.e. phase II include, Novartis.

• Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Cryopyrin-Associated Periodic Syndrome (CAPS) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cryopyrin-Associated Periodic Syndrome (CAPS): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cryopyrin-Associated Periodic Syndrome (CAPS) drugs.

Cryopyrin-Associated Periodic Syndrome (CAPS) Report Insights
• Cryopyrin-Associated Periodic Syndrome (CAPS) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cryopyrin-Associated Periodic Syndrome (CAPS) Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Cryopyrin-Associated Periodic Syndrome (CAPS) drugs?
• How many Cryopyrin-Associated Periodic Syndrome (CAPS) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cryopyrin-Associated Periodic Syndrome (CAPS) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cryopyrin-Associated Periodic Syndrome (CAPS) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Novartis
• Inflazome
• Mabpharm
• Roche

Key Products
• DFV 890
• IZD 334
• Inzomelid
• CMAB 816

❖ レポートの目次 ❖

Introduction
Executive Summary
Cryopyrin-Associated Periodic Syndrome (CAPS): Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Mid Stage Products (Phase II)
• Comparative Analysis
DFV 890: Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
• Comparative Analysis
IZD 334: Inflazome
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report
Inactive Products
• Comparative Analysis
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Products
Cryopyrin-Associated Periodic Syndrome (CAPS)- Unmet Needs
Cryopyrin-Associated Periodic Syndrome (CAPS)- Market Drivers and Barriers
Cryopyrin-Associated Periodic Syndrome (CAPS)- Future Perspectives and Conclusion
Cryopyrin-Associated Periodic Syndrome (CAPS) Analyst Views
Cryopyrin-Associated Periodic Syndrome (CAPS) Key Companies
Appendix



★調査レポート[クリオピリン関連周期症候群(CAPS)の世界市場:パイプラインインサイト2021] (コード:DELV21SE073)販売に関する免責事項を必ずご確認ください。
★調査レポート[クリオピリン関連周期症候群(CAPS)の世界市場:パイプラインインサイト2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆